Phase II study of low-dose cyclophosphamide and ipilimumab in metastatic melanoma.
2014
e20025 Background: Ipilimumab (Ipi) has improved clinical outcomes in metastatic melanoma (MM). Previous data suggested that low doses of cyclophosphamide (ldCTX) may have immunomodulatory effects ...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
3
Citations
NaN
KQI